US Bancorp
SVA

US Bancorp’s Sinovac Biotech, Ltd SVA Stock Holding History

US Bancorp’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-127
Closed – – 4239
2024
Q2 		$0 Buy
+127
New – ﹤0.01% 4166
2023
Q4 		– Sell
-127
Closed – – 4231
2023
Q3 		$0 Hold
127
– – ﹤0.01% 4182
2023
Q2 		$0 Buy
+127
New – ﹤0.01% 4218
2022
Q4 		– Sell
-127
Closed – – 4369
2022
Q3 		$0 Hold
127
– – ﹤0.01% 4338
2022
Q2 		$0 Buy
+127
New – ﹤0.01% 4361
2022
Q1 		– Sell
-127
Closed – – 4315
2021
Q4 		$0 Hold
127
– – ﹤0.01% 4330
2021
Q3 		$0 Buy
+127
New – ﹤0.01% 4270
2015
Q2 		– Sell
-1,500
Closed -$7K – 3770
2015
Q1 		$7K Hold
1,500
– – ﹤0.01% 3235
2014
Q4 		$8K Buy
+1,500
New +$7.65K ﹤0.01% 3188

Other funds holding SVA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
HI
Horizon Investments Charlotte, North Carolina $8.92B AUM 25.62% 1-Year Est. Return

US Bancorp's SVA Position: Q3 2024 in Review

US Bancorp sold out of Sinovac Biotech, Ltd (SVA) in Q3 2024, closing a stake of 127 shares.

US Bancorp first reported a position in SVA in Q4 2014 and held it in 9 quarters. The position peaked at $8K in Q4 2014. 9 funds tracked by Wall St. Rank hold SVA as of Q3 2024.

  • US Bancorp reported no remaining Sinovac Biotech, Ltd position as of Q3 2024 after selling out during the quarter.
  • US Bancorp sold 127 Sinovac Biotech, Ltd shares in Q3 2024.
  • US Bancorp first reported a position in Sinovac Biotech, Ltd in Q4 2014 and held it in 9 quarters.
  • US Bancorp's Sinovac Biotech, Ltd position peaked at $8K in Q4 2014.
  • 9 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q3 2024.

Based on US Bancorp's 13F filing for Q3 2024, filed 28 Oct 2024.